Transgene

TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

07 Apr 25

Updated

01 May 25

n/a

AnalystConsensusTarget's Fair Value

n/a

27.7%

-8.8%

27.7%

-8.8%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

€254.4% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates4

Shared on 01 May 25

Fair value Increased 44%

Shared on 24 Apr 25

Fair value Decreased 31%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Increased 156%

Shared on 09 Apr 25

Fair value Decreased 44%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

€2

54.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

34.60%

Biotech revenue growth rate

9.35%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.47%

Calculation

€1.98m

Earnings '28

158.55x

PE Ratio '28

€314.25m

Market Cap '28

€314.25m

Market Cap '28

131.93m

No. shares '28

€2.38

Share Price '28

€2.38 Share Price '28

Discounted to 2025 @ 5.98% p.a.

€2.00

Fair Value '25